文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

近期紫杉醇类纳米给药系统治疗癌症的临床进展。

Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer.

机构信息

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

出版信息

Int J Nanomedicine. 2020 Oct 22;15:8151-8166. doi: 10.2147/IJN.S272529. eCollection 2020.

DOI:10.2147/IJN.S272529
PMID:33132699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7592152/
Abstract

Conventional taxanes are used as cornerstone of the chemotherapeutical treatment for a variety of malignancies. Nevertheless, a large proportion of patients do not benefit from their treatment while they do suffer from severe adverse events related to the solvent or to the active compound. Cremophor EL and polysorbate 80 free formulations, conjugates, oral formulations and different types of drug delivery systems are some examples of the several attempts to improve the treatment with taxanes. In this review article, we discuss recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of cancer. Targeting mechanisms of drug delivery systems and characteristics of the most commonly used taxane-containing drug delivery systems in the clinical setting will be discussed in this review.

摘要

常规的紫杉烷类药物被用作多种恶性肿瘤化疗治疗的基石。然而，很大一部分患者并没有从治疗中受益，同时他们还遭受着与溶剂或活性化合物相关的严重不良反应。无聚氧乙烯蓖麻油 EL 和聚山梨醇酯 80 制剂、缀合物、口服制剂和不同类型的药物传递系统是几种试图改善紫杉烷类药物治疗的方法的例子。在这篇综述文章中，我们讨论了纳米介导的紫杉烷类药物传递系统治疗癌症的最新临床进展。本文将讨论药物传递系统的靶向机制和临床中最常用的含紫杉烷类药物传递系统的特点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c8/7592152/126363cfe8e1/IJN-15-8151-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c8/7592152/257b24504f92/IJN-15-8151-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c8/7592152/126363cfe8e1/IJN-15-8151-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c8/7592152/257b24504f92/IJN-15-8151-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c8/7592152/126363cfe8e1/IJN-15-8151-g0002.jpg

相似文献

[1]
Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer.

Int J Nanomedicine. 2020-10-22

[2]
A critical review of lipid-based nanoparticles for taxane delivery.

Cancer Lett. 2012-7-13

[3]
Macromolecules as taxane delivery systems.

Expert Opin Drug Deliv. 2010-12-9

[4]
Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics.

Adv Drug Deliv Rev. 2013-11-1

[5]
The intravenous to oral switch of taxanes: strategies and current clinical developments.

Future Oncol. 2021-4

[6]
Taxane anticancer agents: a patent perspective.

Expert Opin Ther Pat. 2016

[7]
Hexagonal Boron Nitrides (White Graphene): A Promising Method for Cancer Drug Delivery.

Int J Nanomedicine. 2019-12-19

[8]
Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review.

Curr Drug Metab. 2015

[9]
Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes.

J Control Release. 2009-11-17

[10]
Nanomedicine and drug delivery.

Med Clin North Am. 2007-9

引用本文的文献

[1]
Enhanced Cytotoxic Effects of Docetaxel-Loaded Solid Lipid Nanoparticles (SLN-DTX) on Gastric Adenocarcinoma In Vitro.

J Biochem Mol Toxicol. 2025-9

[2]
Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity.

Int J Mol Sci. 2022-12-9

[3]
Polysaccharide dextran-based conjugate for selective co-delivery of two synergistic drugs docetaxel and docosahexaenoic acid to tumor cells.

Drug Deliv. 2023-12

[4]
A Novel Dextran-Based Dual Drug Conjugate Targeted Tumors with High Biodistribution Ratio of Tumors to Normal Tissues.

Int J Nanomedicine. 2022

[5]
Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634.

Cancers (Basel). 2021-7-26

[6]
Applications of capillary action in drug delivery.

iScience. 2021-7-1

[7]
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery.

Pharmaceutics. 2021-3-3

[8]
Polymeric Nanoparticles with a Sera-Derived Coating for Efficient Cancer Cell Uptake and Killing.

ACS Omega. 2021-2-19

本文引用的文献

[1]
A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours.

J Control Release. 2020-9-10

[2]
Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors.

Clin Cancer Res. 2020-7-15

[3]
Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis.

Sci Rep. 2020-1-17

[4]
Actively targeted nanocarriers for drug delivery to cancer cells.

Expert Opin Drug Deliv. 2019-5-2

[5]
A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.

Oncologist. 2019-2-22

[6]
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.

Br J Cancer. 2019-2-12

[7]
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.

JAMA Oncol. 2018-10-1

[8]
To reduce premature drug release while ensuring burst intracellular drug release of solid lipid nanoparticle-based drug delivery system with clathrin modification.

Nanomedicine. 2018-5-30

[9]
Polymer Prodrug-Based Nanoreactors Activated by Tumor Acidity for Orchestrated Oxidation/Chemotherapy.

Nano Lett. 2017-10-9

[10]
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.

Med Oncol. 2017-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索